CORAL GABLES, Fla., May 24, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced the pricing of an underwritten offering of 6,000,000 units, with each unit consisting of one share of its common stock and a warrant to purchase up to one share of its common stock, at a public offering price of $0.80 per unit. Catalyst expects to receive net proceeds of approximately $4.0 million (not including any cash proceeds from a future exercise of the warrants), after deducting the underwriting discount and estimated offering expenses. The warrants will have a 5-year term and an exercise price equal to $1.04 per share. The offering is expected to close on May 30, 2012, subject to customary closing conditions.
